The Role and Mechanism of microRNA-1224 in Human Cancer

Ma, Mingwei; Li, Jie; Zhang, Zimu; Sun, Jun; Liu, Zhen; Zeng, Ziyang; Ouyang, Siwen; Kang, Weiming

doi:10.3389/fonc.2022.858892

Cited by 6 publications

(3 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the discovery of miRNA functions in cancer, many miRNAs have been identified in various cancer types 8,13 . Furthermore, additional miRNAs have been found to be specifically dysregulated in different cancer types because of the discovery of novel miRNAs and the development of new detection technologies over the last decade [58][59][60][61] . For example, miR-34697, miR-45165, miR-638, and miR-152 have been identified to play a role in non-small cell lung cancer (NSCLC); miR-885-5p has been identified to play a role in kidney cancer; and miR-1285 has been identified to play a role in prostate cancer 58,62 .…”

Section: Mirnas As Biomarkers Of Cancer Diagnosis and Drug Efficacy P...mentioning

confidence: 99%

MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies

Kim

Croce

2023

Exp Mol Med

View full text Add to dashboard Cite

As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a crucial role in cancer development. Since the discovery of the identity and clinical functions of miRNAs, over the past few decades, the roles of miRNAs in cancer have been actively investigated. Numerous pieces of evidence indicate that miRNAs are pivotal factors in most types of cancer. Recent cancer research focused on miRNAs has identified and characterized a large cohort of miRNAs commonly dysregulated in cancer or exclusively dysregulated in specific types of cancer. These studies have suggested the potential of miRNAs as biomarkers in the diagnosis and prognostication of cancer. Moreover, many of these miRNAs have oncogenic or tumor-suppressive functions. MiRNAs have been the focus of research given their potential clinical applications as therapeutic targets. Currently, various oncology clinical trials using miRNAs in screening, diagnosis, and drug testing are underway. Although clinical trials studying miRNAs in various diseases have been reviewed before, there have been fewer clinical trials related to miRNAs in cancer. Furthermore, updated results of recent preclinical studies and clinical trials of miRNA biomarkers and drugs in cancer are needed. Therefore, this review aims to provide up-to-date information on miRNAs as biomarkers and cancer drugs in clinical trials.

show abstract

Section: Mirnas As Biomarkers Of Cancer Diagnosis and Drug Efficacy P...mentioning

confidence: 99%

MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies

Kim

Croce

2023

Exp Mol Med

View full text Add to dashboard Cite

show abstract

“…The tumor suppressor is effectively hindered by uncontrolled amplification of the miRNA gene that modulates it, which also induces carcinogenesis. Oncogenes or tumor-suppressor genes can function as miRNAs ( Ma M. et al, 2022 ). The initial miRNAs identified as silencers were miR-16a and miR-15o, which are expressed in site 13q14, and are present in more than 50% of those with chronic leukemia ( Braga et al, 2022 ).…”

Section: Role Of Mirna As Proto-oncogene and Oncogenementioning

confidence: 99%

Pharmacological impact of microRNAs in head and neck squamous cell carcinoma: Prevailing insights on molecular pathways, diagnosis, and nanomedicine treatment

Bhattacharjee¹,

Syeda

Rynjah³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma is a disease that most commonly produce tumours from the lining of the epithelial cells of the lips, larynx, nasopharynx, mouth, or oro-pharynx. It is one of the most deadly forms of cancer. About one to two percent of all neo-plasm-related deaths are attributed to head and neck squamous cell carcinoma, which is responsible for about six percent of all cancers. MicroRNAs play a critical role in cell proliferation, differentiation, tumorigenesis, stress response, triggering apoptosis, and other physiological process. MicroRNAs regulate gene expression and provide new diagnostic, prognostic, and therapeutic options for head and neck squamous cell carcinoma. In this work, the role of molecular signaling pathways related to head and neck squamous cell carcinoma is emphasized. We also provide an overview of MicroRNA downregulation and overexpression and its role as a diagnostic and prognostic marker in head and neck squamous cell carcinoma. In recent years, MicroRNA nano-based therapies for head and neck squamous cell carcinoma have been explored. In addition, nanotechnology-based alternatives have been discussed as a promising strategy in exploring therapeutic paradigms aimed at improving the efficacy of conventional cytotoxic chemotherapeutic agents against head and neck squamous cell carcinoma and attenuating their cytotoxicity. This article also provides information on ongoing and recently completed clinical trials for therapies based on nanotechnology.

show abstract

“…At present, the involvement of miRNA from KSHV and host cells in the regulation of latent and lytic switches has received more and more attention ( Alomari and Totonchy, 2020 ; Kumar et al, 2022 ). miRNA is a class of small endogenous non-coding RNAs that can simultaneously regulate multiple target genes and play a unique tumor suppressive role in tumor occurrence, development, and metastasis through inhibition or degradation of the RNA translation ( Hussein et al, 2019 ; Liu et al, 2019 ; Ma et al, 2022 ). Wu et al (2022) reported that low-expressed miR-34a-5p in KSHV-infected cells could regulate the level of c-Fos and target the 3′-UTR region, thereby inhibiting cell proliferation and the expression of KSHV-related genes; thus miR-34a-5p may be used as a nucleic acid drug for the treatment of KSHV infection.…”

Section: Introductionmentioning

confidence: 99%

Targeted delivery of miR-34a-5p by phenylborate-coupled polyethylenimide nanocarriers for anti-KSHV treatment

Li,

Cao,

Yao

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Kaposi’s sarcoma-associated herpesvirus (KSHV) can infect a variety of cells and cause malignant tumors. At present, the use of microRNA (miRNA) for anti-KSHV is a promising treatment strategy, but the instability and non-specific uptake of miRNA still limit its use in the treatment of KSHV. In the present study, we constructed a nano-drug delivery system employing chemical grafting and electrostatic adsorption to solve the problems of easy degradation and low cell uptake of miRNA during direct administration. This nano-drug delivery system is to graft 4-carboxyphenylboric acid (PBA) and lauric acid (LA) onto polyethylenimine (PEI) through amidation reaction, and then prepare cationic copolymer nanocarriers (LA-PEI-PBA). The drug-carrying nanocomplex LA-PEI-PBA/miR-34a-5p was formed after further electrostatic adsorption of miR-34a-5p on the carrier and could protect miR-34a-5p from nuclease and serum degradation. Modification of the drug-carrying nanocomplex LA-PEI-PBA/miR-34a-5p by targeted molecule PBA showed effective uptake, increase in the level of miR-34a-5p, and inhibition of cell proliferation and migration in KSHV-infected cells. In addition, the drug-carrying nanocomplex could also significantly reduce the expression of KSHV lytic and latent genes, achieving the purpose of anti-KSHV treatment. In conclusion, these cationic copolymer nanocarriers with PBA targeting possess potential applications in nucleic acid delivery and anti-KSHV therapy.

show abstract

The Role and Mechanism of microRNA-1224 in Human Cancer

Cited by 6 publications

References 62 publications

MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies

MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies

Pharmacological impact of microRNAs in head and neck squamous cell carcinoma: Prevailing insights on molecular pathways, diagnosis, and nanomedicine treatment

Targeted delivery of miR-34a-5p by phenylborate-coupled polyethylenimide nanocarriers for anti-KSHV treatment

Contact Info

Product

Resources

About